April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Chemoreduction for Group E Retinoblastoma in 76 Eyes
Author Affiliations & Notes
  • C. L. Shields
    Oncology Service, Wills Eye Institute, Philadelphia, Pennsylvania
  • A. Ramasubramanian
    Oncology Service, Wills Eye Institute, Philadelphia, Pennsylvania
  • A. Thangappan
    Oncology Service, Wills Eye Institute, Philadelphia, Pennsylvania
  • K. Hartzell
    Oncology Service, Wills Eye Institute, Philadelphia, Pennsylvania
  • J. A. Shields
    Oncology Service, Wills Eye Institute, Philadelphia, Pennsylvania
  • Footnotes
    Commercial Relationships  C.L. Shields, None; A. Ramasubramanian, None; A. Thangappan, None; K. Hartzell, None; J.A. Shields, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 1688. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C. L. Shields, A. Ramasubramanian, A. Thangappan, K. Hartzell, J. A. Shields; Chemoreduction for Group E Retinoblastoma in 76 Eyes. Invest. Ophthalmol. Vis. Sci. 2009;50(13):1688.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the success of chemoreduction for group E retinoblastoma (Rb).

Methods: : Retrospective chart review

Results: : Of the 64 eyes in the chemoreduction (CRD) group 25% were salvaged with CRD alone and 20% with CRD and therapeutic [standard dose] external beam radiation (T-EBRT), while 34% were enucleated following CRD alone and 20% following CRD+T-EBRT. Of the 12 eyes in the CRD + prophylactic [low dose] external beam radiation (P-EBRT) group, 83% were salvaged with CRD+P-EBRT, while 17% were enucleated and none required T-EBRT.

Keywords: clinical (human) or epidemiologic studies: outcomes/complications • tumors • retina 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×